Page 1 of 20
NSG 124 Pharmacology
EXAM I Test Plan
Unit 1 Module 1 and 2 Location Student Notes
Assessing Pain and pain management: NSG124.01.01.01
a. defining goals DEFINING GOALS- THE GOAL OF DRUG THERAPY IS TO PRODUCE
b. identifying interventions MAXIMUM BENEFIT WITH MINIMAL HARM. *MAXIMIZE THERAPEUTIC
c. evaluating success RESPONSES WHILE PREVENTING OR MINIMIZING ADVERSE
REACTIONS*
IDENTIFYING INTERVENTIONS- THE NURSE MUST CONSIDER
DOSAGE AND ROUTE OF ADMINISTRATION AS WELL AS TIMING
(WITH RESPECT TO MEALS AND OTHER DRUGS).
FOUR MAJOR GROUPS:
-DRUG ADMINISTRATION.
-INTERVENTIONS TO ENHANCE THERAPEUTIC EFFECTS.
-INTERVENTIONS TO MINIMIZE ADVERSE EFFECTS AND
INTERACTIONS.
-PATIENT EDUCATION.
EVALUATING SUCCESS- SUMMARY OF MONITORING,
EVALUATING THERAPEUTIC EFFECTS, MINIMIZING ADVERSE
EFFECTS AND INTERACTIONS, AND MANAGING TOXICITY.
THE PATIENT MUST BE EVALUATED FOR:
-THERAPEUTIC RESPONSES.
-ADVERSE DRUG REACTIONS AND INTERACTIONS.
-ADHERENCE TO PRESCRIBED REGIMEN.
-SATISFACTION WITH TREATMENT.
, Page 2 of 20
Drug Names NSG124.01.01.02 NONPROPRIETARY (GENERIC)- LESS COMPLEX THAN THE
a. Generic CHEMICAL NAME; FINAL SYLLABULS INDICATE PHARM CLASS. *HAS
b. Proprietary ONLY ONE*
PROPRIETARY (BRAND)- NAMES UNDER WHICH A DRUG IS
MARKETED; CREATED BY DRUG COMPANIES. *SINGLE DRUG MAY
HAVE SEVERAL*
Over the Counter Meds NSG124.01.01.03 OTC MEDS:
a. Assessment x2
b. Education, ASSESSMENT- WHEN USED PROPERLY, THEY PROVIDE RELIEF
Medication food interactions FOR MANY ALIMENTS WHILE SAVING CONUSMERS THE EXPENSE
AND INCONVINENCE OF VISITING PERSCRIBER.
EDUCATION- NEWSLETTERS, REFERENCE BOOKS, AND THE
INTERNET.
MEDICATION FOOD INTERACTIONS- MAY RESULT IN TOXICITY
OR THERAPEUTIC FAILURE.
IMPACT OF FOOD ON DRUG ABSORPTION:
-DECREASED ABSORPTION.
-INCREASED ABSORPTION.
-IMPACT ON DRUG METABOLISM.
-IMPACT ON DRUG TOXICITY.
-TIMING.
NOTE ACTUAL FOOD INTERACTIONS
Major Pharmacokinetics Processes: NSG 124.01.01.04 MEDICATIOIN ABSORPTION- THE MOVEMENT OF A DRUG FROM
a. Medication absorption x2 SITE OF ADMINISTRATION TO BLOOD; THE RATE DETERMINES HOW
b. Medication distribution SOON THE EFFECTS WILL BEGIN. *AMOUNT OF ABSORPTION
c. Medication metabolism DETERMINES HOW INTENSE THE EFFECTS WILL BE*
d. Medication excretion
Assessment and Evaluation MEDICATION DISTRIBUTION- DRUG MOVEMENT FROM THE
, Page 3 of 20
BLOOD TO INTERSTITIAL SPACE OF TISSUES AND INTO CELLS.
MEDICATION METABOLISM- BIOTRANSFORMATION: DEFINED AS
CHEMICAL ALTERATION OF DRUG STRUCTURE.
THERAPEUTIC CONSEQUENCES:
-ACCELERATED RENAL EXCRETION.
-DRUG INACTIVATION.
-INCREASES THERAPEUTIC ACTION.
-ACTIVATION OF “PRO-DRUGS.”
-INCREASED AND DECREASED TOXICITY.
MEDICATION EXCRETION- PROCESS OF DRUG REMOVAL FROM
THE BODY.
Drug levels and half life NSG124.01.01.05 HALF-LIFE- THE TIME REQUIRED FOR THE AMOUNT OF DRUG IN
a. Half-life x2 THE BODY TO DECREASE BY 50%; CAN BE MINUTES OR EXCEED A
b. First-pass effect WEEK.
c. Renal Medication excretion
d. Therapeutic Index SHORT- LEAVE QUICKLY.
LONG- LEAVE SLOWLY.
FIRST-PASS EFFECT- RAPID HEPATIC INACTIVATION OF SOME
ORAL DRUGS; *OCCURS DURING METABOLISM*
RENAL MEDICATION EXCRETION-THE MAJORITY OF THE DRUGS
ARE METABOLISED THROUGH THE KIDNEY.
THERAPEUTIC INDEX- A MEASURE OF A DRUGS SAFETY AND
DETERMINED USING LABORATORY ANIMALS.
LARGE INDEX- INDICATES A DRUG IS RELATIVELY SAFE.
SMALL INDEX- INDICATES A DRUG IS RELATIVELY UNSAFE.
NSG 124 Pharmacology
EXAM I Test Plan
Unit 1 Module 1 and 2 Location Student Notes
Assessing Pain and pain management: NSG124.01.01.01
a. defining goals DEFINING GOALS- THE GOAL OF DRUG THERAPY IS TO PRODUCE
b. identifying interventions MAXIMUM BENEFIT WITH MINIMAL HARM. *MAXIMIZE THERAPEUTIC
c. evaluating success RESPONSES WHILE PREVENTING OR MINIMIZING ADVERSE
REACTIONS*
IDENTIFYING INTERVENTIONS- THE NURSE MUST CONSIDER
DOSAGE AND ROUTE OF ADMINISTRATION AS WELL AS TIMING
(WITH RESPECT TO MEALS AND OTHER DRUGS).
FOUR MAJOR GROUPS:
-DRUG ADMINISTRATION.
-INTERVENTIONS TO ENHANCE THERAPEUTIC EFFECTS.
-INTERVENTIONS TO MINIMIZE ADVERSE EFFECTS AND
INTERACTIONS.
-PATIENT EDUCATION.
EVALUATING SUCCESS- SUMMARY OF MONITORING,
EVALUATING THERAPEUTIC EFFECTS, MINIMIZING ADVERSE
EFFECTS AND INTERACTIONS, AND MANAGING TOXICITY.
THE PATIENT MUST BE EVALUATED FOR:
-THERAPEUTIC RESPONSES.
-ADVERSE DRUG REACTIONS AND INTERACTIONS.
-ADHERENCE TO PRESCRIBED REGIMEN.
-SATISFACTION WITH TREATMENT.
, Page 2 of 20
Drug Names NSG124.01.01.02 NONPROPRIETARY (GENERIC)- LESS COMPLEX THAN THE
a. Generic CHEMICAL NAME; FINAL SYLLABULS INDICATE PHARM CLASS. *HAS
b. Proprietary ONLY ONE*
PROPRIETARY (BRAND)- NAMES UNDER WHICH A DRUG IS
MARKETED; CREATED BY DRUG COMPANIES. *SINGLE DRUG MAY
HAVE SEVERAL*
Over the Counter Meds NSG124.01.01.03 OTC MEDS:
a. Assessment x2
b. Education, ASSESSMENT- WHEN USED PROPERLY, THEY PROVIDE RELIEF
Medication food interactions FOR MANY ALIMENTS WHILE SAVING CONUSMERS THE EXPENSE
AND INCONVINENCE OF VISITING PERSCRIBER.
EDUCATION- NEWSLETTERS, REFERENCE BOOKS, AND THE
INTERNET.
MEDICATION FOOD INTERACTIONS- MAY RESULT IN TOXICITY
OR THERAPEUTIC FAILURE.
IMPACT OF FOOD ON DRUG ABSORPTION:
-DECREASED ABSORPTION.
-INCREASED ABSORPTION.
-IMPACT ON DRUG METABOLISM.
-IMPACT ON DRUG TOXICITY.
-TIMING.
NOTE ACTUAL FOOD INTERACTIONS
Major Pharmacokinetics Processes: NSG 124.01.01.04 MEDICATIOIN ABSORPTION- THE MOVEMENT OF A DRUG FROM
a. Medication absorption x2 SITE OF ADMINISTRATION TO BLOOD; THE RATE DETERMINES HOW
b. Medication distribution SOON THE EFFECTS WILL BEGIN. *AMOUNT OF ABSORPTION
c. Medication metabolism DETERMINES HOW INTENSE THE EFFECTS WILL BE*
d. Medication excretion
Assessment and Evaluation MEDICATION DISTRIBUTION- DRUG MOVEMENT FROM THE
, Page 3 of 20
BLOOD TO INTERSTITIAL SPACE OF TISSUES AND INTO CELLS.
MEDICATION METABOLISM- BIOTRANSFORMATION: DEFINED AS
CHEMICAL ALTERATION OF DRUG STRUCTURE.
THERAPEUTIC CONSEQUENCES:
-ACCELERATED RENAL EXCRETION.
-DRUG INACTIVATION.
-INCREASES THERAPEUTIC ACTION.
-ACTIVATION OF “PRO-DRUGS.”
-INCREASED AND DECREASED TOXICITY.
MEDICATION EXCRETION- PROCESS OF DRUG REMOVAL FROM
THE BODY.
Drug levels and half life NSG124.01.01.05 HALF-LIFE- THE TIME REQUIRED FOR THE AMOUNT OF DRUG IN
a. Half-life x2 THE BODY TO DECREASE BY 50%; CAN BE MINUTES OR EXCEED A
b. First-pass effect WEEK.
c. Renal Medication excretion
d. Therapeutic Index SHORT- LEAVE QUICKLY.
LONG- LEAVE SLOWLY.
FIRST-PASS EFFECT- RAPID HEPATIC INACTIVATION OF SOME
ORAL DRUGS; *OCCURS DURING METABOLISM*
RENAL MEDICATION EXCRETION-THE MAJORITY OF THE DRUGS
ARE METABOLISED THROUGH THE KIDNEY.
THERAPEUTIC INDEX- A MEASURE OF A DRUGS SAFETY AND
DETERMINED USING LABORATORY ANIMALS.
LARGE INDEX- INDICATES A DRUG IS RELATIVELY SAFE.
SMALL INDEX- INDICATES A DRUG IS RELATIVELY UNSAFE.
